User menu

Axillary lymph node metastasis in recurrence of papillary thyroid carcinoma: a case report.

Bibliographic reference Ers, Vincent ; Galant, Christine ; Malaise, Jacques ; Rahier, Jacques ; Daumerie, Chantal. Axillary lymph node metastasis in recurrence of papillary thyroid carcinoma: a case report.. In: Wiener klinische Wochenschrift, Vol. 118, no. 3-4, p. 124-7 (2006)
Permanent URL http://hdl.handle.net/2078.1/10589
  1. Haid A, Knauer M, Koberle-Wuhrer R, Wenzl E (2005) Sentinel node biopsy in breast cancer: techniques and indications. Wien Klin Wochenschr 117: 121–128
  2. de Andrade JM, Marana HR, Sarmento Filho JM, Murta EF, Vellud MA, Bighetti S (1996) Differential diagnosis of axillary masses. Tumori 82: 596–599
  3. Jaffer S, Goldfarb AB, Gold JE, Szporn A, Bleiweiss IJ (1995) Contralateral axillary lymph node metastasis as the first evidence of locally recurrent breast carcinoma. Cancer 75: 2875–2878
  4. Koike K, Fujii T, Yanaga H, Nakagawa S, Yokoyama G, Yahara T, Hanzawa M, Kato S, Shirouzu K (2004) Axillary lymph node recurrence of papillary thyroid microcarcinoma: report of a case. Surg Today 34: 440–443
  5. Schlumberger M, Parmentier C, de Vathaire F, Tubiana M (1997) Iodine-131 and External Radiation in the Treatment of Local and Metastatic Thyroid Cancer. In: Falk SA (ed) Thyroid disease: endocrinology, surgery, medicine and radiotherapy, 2nd edn. Lippincott-Raven, Philadelphia, p 612
  6. Auersperg M, Us-Krsovec M, Petric G, Pogacnik, Besic N (1990) Results of combined modality treatment in poorly differentiated and anaplastic thyroid carcinoma. Wien Klin Wochenschr 102: 267–270
  7. Grunwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, et al (1999) Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 26: 1547–1552
  8. Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, et al (1999) [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic 131-I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84: 2291–2302
  9. Alnafisi NS, Driedger AA, Coates G, Moote DJ, Raphael SJ (2000) FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. J Nucl Med 41: 1010–1015
  10. Muros MA, Llamas-Elvira JM, Ramirez-Navarro A, Acosta Gomez MJ, Rodriguez-Fernandez A, Muros T, et al (2000) Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. Am J Surg 179: 457–461
  11. Schlüter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M (2001) Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I Scan. J Nucl Med 42: 71–76
  12. Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, et al (2000) Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 85: 1107–1113